The termination removes near-term dilution overhang, which is a positive for existing shareholders, but for a $7M market-cap pre-revenue biotech, the loss of the ATM facility significantly increases cash-runway risk. Monitor the upcoming 10-Q for cash position and any alternative financing arrangements.
Price Chart
Executive Summary
AIM ImmunoTech mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, closing off its primary equity financing channel. The company had raised approximately $2.8 million in gross proceeds from selling 3,200,736 shares under the agreement since April 2025. With a $7M market cap and no penalty for termination, this removes future dilution risk but also eliminates a key funding source for a pre-revenue biotech, raising going-concern pressure.
Key Facts
- Mutual termination of Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026.
- No termination penalties incurred.
- From April 1, 2025 to July 31, 2026, the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8 million.
- Company will not offer or sell any additional shares under the agreement or related prospectus.
- Market cap is approximately $7M, making the loss of the ATM facility a material funding constraint.
Financial Impact
Termination of the sole equity financing facility that raised ~$2.8M over 16 months; no termination fees; future equity capital access eliminated.
Risk Factors
- Loss of primary equity financing source for a pre-revenue company increases liquidity risk.
- Potential need for dilutive alternative financing (e.g., private placement, convertible note) at unfavorable terms.
- Going-concern risk if cash runway is insufficient without the ATM facility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036104 |
| Document: 0001493152-26-036104-index-headers.html | 0001493152-26-036104 |
| Document: 0001493152-26-036104-index.html | 0001493152-26-036104 |
| Document: 0001493152-26-036104.txt | 0001493152-26-036104 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers